EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study

Hiroaki Takahashi iD, Yoko Saito, Kanon Sugawara, Masaki Sato, Tomohiko Tairabune, Haruki Ujiie iD, Junichi Asaka, Kenzo Kudo

Cancer Chemotherapy and Pharmacology · 2024

DOI: 10.1007/s00280-023-04619-3 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2024. Verfasst von Hiroaki Takahashi und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, 1-1-1 Idaido…. Hauptthemen laut MEDLINE: Exanthema, Colorectal Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: the Japan Society for the Promotion of Science KAKENHI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Acneiform rash is frequently observed in patients undergoing cancer treatment with anti-epidermal growth factor receptor (EGFR) antibody drugs and can often necessitate treatment discontinuation. However, the specific changes in skin parameters resulting from anti-EGFR antibody drug administration are poorly understood. Therefore, this study aimed to longitudinally and quantitatively evaluate the changes in skin parameters (transepidermal water loss [TEWL], hydration level, and sebum level) caused by anti-EGFR antibody drugs and investigate their potential as control markers for skin disorders. METHODS: This prospective study included 12 patients with colorectal cancer who received anti-EGFR antibody drugs for the first time. The assessment items included the grade of acneiform rash and skin parameters (TEWL, hydration level, and sebum level), which were observed for up to 6 weeks after administration of the medication. RESULTS: The enrolled patients were classified into two groups based on the grade of acneiform rash caused by anti-EGFR antibody drugs: "Grade 1 and lower," and "Grade 2 and higher." The skin parameters were compared between these groups. The results showed that in the "Grade 2 and higher" group, TEWL in the face (at week 2 of administration), chest (baseline, weeks 2 and 6 of administration), and back (at week 2 of administration) were significantly higher than those in the "Grade 1 and lower" group. However, the two groups showed no significant differences in hydration or sebum levels at any time point. CONCLUSION: TEWL can serve as a marker for acneiform rashes induced by anti-EGFR antibody drugs during cancer treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ExanthemaColorectal NeoplasmsHumansPanitumumabProspective StudiesErbB ReceptorsSkinCetuximab

Stichwörter der Autor:innen

Acneiform rashAnti-EGFR antibody drugColorectal cancerSkin parametersTransepidermal water loss

Substanzen

PanitumumabErbB ReceptorsCetuximab

Autor:innen und Institutionen

  • Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3694, Japan. hiroakit@iwate-med.…
  • Department of Pharmacy, Iwate Medical University Hospital, 2-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3695, Japan. hiroakit@iwate-med.ac.jp.
  • Department of Pharmacy, Iwate Medical University Hospital, 2-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3695, Japan.
  • Regina Pharmacy, 3-2-4 Kandajimbocho, Chiyoda-ku, Tokyo, 101-0051, Japan.
  • Division of Integrated Information for Pharmaceutical Sciences, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3694, Japan.
  • Division of Clinical Pharmaceutics and Pharmacy Practice, Department of Clinical Pharmacy, School of Pharmacy, Iwate Medical University, 1-1-1 Idaidori, Yahaba-cyo, Shiwa-gun, Iwate, 028-3694, Japan.

ORCID-Profile: Hiroaki Takahashi, Haruki Ujiie

Förderung

  • the Japan Society for the Promotion of Science KAKENHI

Zitieren

APA

Takahashi, H., Saito, Y., Sugawara, K., Sato, M., Tairabune, T., Ujiie, H., Asaka, J., & Kudo, K. (2024). Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-023-04619-3

Vancouver

Takahashi H, Saito Y, Sugawara K, Sato M, Tairabune T, Ujiie H, et al. Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study. Cancer Chemotherapy and Pharmacology. 2024. doi:10.1007/s00280-023-04619-3

BibTeX
@article{Takahashi2024,
  author = {Takahashi, Hiroaki and Saito, Yoko and Sugawara, Kanon and Sato, Masaki and Tairabune, Tomohiko and Ujiie, Haruki and Asaka, Junichi and Kudo, Kenzo},
  title = {Quantitative assessment of skin disorders induced by panitumumab: a prospective observational study},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2024},
  doi = {10.1007/s00280-023-04619-3}
}
Kostenlos starten →